Aged ; Humans ; Male ; Neuroleptic Malignant Syndrome ; etiology ; physiopathology ; Parkinson Disease ; drug therapy ; Substance Withdrawal Syndrome

OBJECTIVE: To compare the clinical efficacy between auricular point sticking combined with transcutaneous electrical acupoint stimulation (TEAS) and nicotine patch for smoking cessation. METHODS: Two hundred patients who voluntarily quit smoking were randomly divided into a combination group and a nicotine patch group, 100 cases in each group. In the combination group, auricular point sticking (Shenmen [TF₄], Neifenmi [CO₁₈], Pizhixia [AT₄], Jiaogan [AH_6a], etc., once every other day) combined with TEAS（Lieque [LU 7] and Zusanli [ST 36], with continuous wave, 20 Hz in frequency, 1 mA in current intensity, 30 min each time, once a day) were applied. In the nicotine patch group, nicotine patch was applied. Both groups were treated for 8 weeks. The immediate withdrawal rate and persistent withdrawal rate 8 weeks into treatment and in follow-up of 16 weeks after treatment in the two groups were compared; before treatment, 8 weeks into treatment and in follow-up of 16 weeks after treatment, the degree of nicotine dependence was evaluated by using Fagerström test for nicotine dependence (FTND); 1 week into treatment, 8 weeks into treatment and in follow-up of 16 weeks after treatment, the withdrawal symptoms and smoking craving were evaluated by using Minnesota nicotine withdrawal scale (MNWS); the safety and compliance (dropped off rate and treatment completeness) were evaluated in the two groups. RESULTS: There was no statistical significance of the differences in the immediate withdrawal rate and persistent withdrawal rate 8 weeks into treatment and during follow-up between the two groups (P>0.05). The FTND scores were decreased 8 weeks into treatment and during follow-up in the two groups compared with those before treatment (P<0.01); the FTND score during follow-up in the combination group was lower than the nicotine patch group (P<0.05). The MNWS scores were decreased 8 weeks into treatment and during follow-up in the two groups compared with those 1 week into treatment (P<0.05); the changes of MNWS scores 8 weeks into treatment and during follow-up in the combination group were greater than the nicotine patch group (P<0.05, P<0.01). There were no serious adverse reactions in either group. Eight weeks into treatment and during follow-up, the dropped off rates were all 16.0% (16/100) in the combination group, which were 20.0% (20/100) and 23.0% (23/100) in the nicotine patch group, there was no statistical significance of the differences in the two groups (P>0.05). There was no significant difference in treatment completeness between the two groups (P>0.05). CONCLUSION Auricular point sticking combined with TEAS could effective decrease the degree of nicotine dependence, improve withdrawal symptoms in smokers, its effect is superior to nicotine patch.
Humans ; Smoking Cessation ; Tobacco Use Disorder ; Acupuncture Points ; Administration, Cutaneous ; Nicotine ; Substance Withdrawal Syndrome/drug therapy*

OBJECTIVE: To explore the change and influence factors of quality of life QOL for drug abusers who accepted methadone maintenance treatment (MMT). METHODS: The questionnaire of QOL-BRIEF was used to measure the level of QQL when patients just entered the study and 6 months after the treatment respectively. The effect of therapy and characteristic of patients on change of QOL was analyzed. RESULTS: The scores in physiological domain, psychological domain, and the total score obviously increased after the treatment. There was no significant difference in the change of QOL between the patients of different dose groups. The QOLs of males and patients with long-time drug use improved significantly after the treatment. CONCLUSION MMT can raise the QOL of drug abusers. Gender and time of drug use may be the risk factors of QOL improvement.
Female ; Humans ; Male ; Methadone ; administration & dosage ; Opioid-Related Disorders ; drug therapy ; Quality of Life ; Substance Withdrawal Syndrome ; drug therapy ; Surveys and Questionnaires

Adult ; Female ; Glucocorticoids ; administration & dosage ; Humans ; Male ; Radiography, Thoracic ; Severe Acute Respiratory Syndrome ; diagnostic imaging ; drug therapy ; Substance Withdrawal Syndrome

OBJECTIVE: To explore the change and impact factors of craving for heroin in patients after 6 month methadone maintenance treatment (MMT). METHODS: The questionnaire of craving for heroin was used to measure the level of craving for heroin when patients just entered the study and were treated for 6 months. The influence of MMT on craving in patients were analyzed. RESULTS: The total score and score for other factors decreased except the factor "self-control" after MMT. The craving for high dose patients decreased significantly after 6 month treatment (P<0.05). The degree of craving for heroin in males and females all decreased after MMT, but no significant difference was shown (P>0.05). The craving degree for heroin in patients with long drug use was higher than that of patients with short drug use. After the treatment, the improvement of craving was more significant for the long drug users. CONCLUSION MMT can decline the craving for heroin in drug users. Dosage for methadone and gender may be the risk factors of craving change.
Adult ; China ; Female ; Heroin Dependence ; drug therapy ; psychology ; rehabilitation ; Humans ; Male ; Methadone ; therapeutic use ; Substance Withdrawal Syndrome ; drug therapy ; psychology ; Surveys and Questionnaires ; Young Adult

OBJECTIVE: To investigate the efficacy and safety of Ji-Tai tablet and Ji-Tai tablet combined with buprenorphine in the treatment of patients with acute withdrawal syndrome of mild heroin dependence. METHODS: A total of 150 patients with mild heroin dependence were recruited, and were randomly assigned to a Ji-Tai tablet group (n=50), a Ji-Tai tablet combined with buprenorphine group (n=50) and a control group (n=50) during a 10-day clinical trial. Opiate withdrawal scale (OWS) was used to measure the severity of withdrawal symptoms. Anxiety symptoms assessments were made at 0 day (baseline), the day 5 (middle), and the day 10 (end) by the Hamilton anxiety scale (HAMA). Symptoms were assessed before and 1 h or 2 h after medication each day. The total withdrawal symptoms scores and the daily reduction rate were used to measure the effect of Ji-Tai tablet vs Ji- Tai tablet plus buprenorphine. Safety evaluation was carried out by the following measures: baseline of treatment, drug side effects after the treatment, vital signs (blood pressure, heart rate, and respiration rate), laboratory examination (routine blood and urine tests and the liver and kidney function tests), and electrocardiograms. RESULTS: A total of 142 mild heroin dependence patients performed the experiments (including 48 in the Ji-Tai tablet group, 48 in the Ji-Tai tablet with buprenorphine group and 46 in the control group). The scores of baseline withdrawal symptoms were 43.520±19.786, 42.640±17.648 and 47.100±24.450, respectively, with no significant differences among the 3 groups (all P>0.05 ). During the 10-day treatment, the reduction rate of acute withdrawal symptoms scores increased daily, the acute withdrawal syndrome scores and the anxiety symptoms scores declined from day 0 to day 10, there was also no significant difference among the 3 groups (all P>0.05). Ji-Tai tablet did not affect vital signs such as blood pressure, heart rate, and respiration rate. CONCLUSION Ji-Tai tablet or Ji-Tai tablet combined with buprenorphine had no effect on acute withdrawal symptoms of mild heroin dependence.
Anxiety ; Buprenorphine ; therapeutic use ; Double-Blind Method ; Drugs, Chinese Herbal ; therapeutic use ; Heroin Dependence ; drug therapy ; Humans ; Substance Withdrawal Syndrome ; drug therapy ; Tablets

Pharmacologic and cognitive-behaviral treatments are currently employed in the treatment of panic disorder. Several studies have found that a combination of the two treatment modalities may be superior to either treatment alone. Antidepressants has been considered as the first line of treatment for patients with panic disoreder since 1960s. Although tricyclic antidepressants (TCAs) such as imipramine and clomipramine are well established in treating panic disorder, today many clinicians choose selective serotonin reuptake inhibitors(SSRIs) as the first-line drug because of their efficacy, safely, and favorable side effect profile. While many clinicians have chosen the SSRIs as the antipanic drug of choice, research support for this preference is just starting to emerge. Since a substantial number of patients with panic disorder are quite sensitive to the unpleasent activating effects of antidepressants including TCAs and SSRIs, it is prudent to start the patients on a low dose. Monoamine oxidase inhibitors(MAOIs) have established efficacy as antipanic drugs. These medications may be particularly effective in treament-resistant patients. Also, it is expected that new antidepressants, such as nefazodone and venlafaxine, have antipanic properties. With the advent of high-potency benzodiazepines(e.g. alprazolam, clonazepam), these drugs have been major antipanic drugs. However, the major limitations related to benzodiazepine use are dependency and withdrawal symptoms. Generally, if a benzodiazepine is used for more than about 1 month of treatment, the drug should be discontinued at a slow rate and the patient should receive support for any distressing withdrawal symptoms.
Alprazolam ; Antidepressive Agents ; Antidepressive Agents, Tricyclic ; Benzodiazepines ; Clomipramine ; Drug Therapy* ; Humans ; Imipramine ; Monoamine Oxidase ; Panic Disorder* ; Panic* ; Serotonin ; Substance Withdrawal Syndrome ; Venlafaxine Hydrochloride

Alcohol use disorder is a kind of chronic illness that is difficult to treat. The disorder often recurs easily and patients visit the outpatient clinic while intoxicated. Therefore, is often too difficult to treat all people of concern, i.e., the caregiver, patient, and doctor, due to the frequent helpless and hopeless relapse. If the patient has severe withdrawal symptoms or poor physical condition, it is very difficult to maintain treatment at an outpatient clinic. On the other hand, many patients abstain or reduce drinking and go on to live a sober life by outpatient-based management. In addition, psychosocial treatment techniques and efficient medications are available at the level of a psychiatric outpatient clinic. Under the scope and limitations of outpatient-based approaches, patients with alcohol use disorder can develop a new life called ‘recovery’ with the help of psychiatrists, by the way of motivating changes, correcting cognitive errors, establishing effective coping skills, utilizing external resources actively, and facilitating healthy roles with their families.
Adaptation, Psychological ; Alcoholism ; Ambulatory Care Facilities ; Caregivers ; Chronic Disease ; Drinking ; Drug Therapy ; Hand ; Humans ; Outpatients ; Psychiatry ; Psychotherapy ; Recurrence ; Substance Withdrawal Syndrome

A series of chemotherapeutic drugs that induce DNA damage, such as cisplatin (DDP), are standard clinical treatments for ovarian cancer, testicular cancer, and other diseases that lack effective targeted drug therapy. Drug resistance is one of the main factors limiting their application. Sensitizers can overcome the drug resistance of tumor cells, thereby enhancing the antitumor activity of chemotherapeutic drugs. In this study, we aimed to identify marketable drugs that could be potential chemotherapy sensitizers and explore the underlying mechanisms. We found that the alcohol withdrawal drug disulfiram (DSF) could significantly enhance the antitumor activity of DDP. JC-1 staining, propidium iodide (PI) staining, and western blotting confirmed that the combination of DSF and DDP could enhance the apoptosis of tumor cells. Subsequent RNA sequencing combined with Gene Set Enrichment Analysis (GSEA) pathway enrichment analysis and cell biology studies such as immunofluorescence suggested an underlying mechanism: DSF makes cells more vulnerable to DNA damage by inhibiting the Fanconi anemia (FA) repair pathway, exerting a sensitizing effect to DNA damaging agents including platinum chemotherapy drugs. Thus, our study illustrated the potential mechanism of action of DSF in enhancing the antitumor effect of DDP. This might provide an effective and safe solution for combating DDP resistance in clinical treatment.
Female ; Male ; Humans ; Cisplatin/pharmacology* ; Disulfiram/pharmacology* ; Testicular Neoplasms/drug therapy* ; Fanconi Anemia/drug therapy* ; Alcoholism/drug therapy* ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Substance Withdrawal Syndrome/drug therapy* ; Apoptosis ; Antineoplastic Agents/therapeutic use* ; Cell Proliferation

This study examined the effects of combined administration of tyrosine, lecithin, L-glutamine and L-5-hydroxytryptophan (5-HTP) on heroin withdrawal syndromes and mental symptoms in detoxified heroin addicts. In the cluster-randomized placebo-controlled trial, 83 detoxified heroin addicts were recruited from a detoxification treatment center in Wuhan, China. Patients in the intervention group (n=41) were given the combined treatment with tyrosine, lecithin, L-glutamine and 5-HTP and those in the control group (n=42) were administered the placebo. The sleep status and the withdrawal symptoms were observed daily throughout the study, and the mood states were monitored pre- and post-intervention. The results showed that the insomnia and withdrawal scores were significantly improved over time in participants in the intervention group as compared with those in the control group. A greater reduction in tension-anxiety, depression-dejection, anger-hostility, fatigue-inertia and total mood disturbance, and a greater increase in their vigor-activity symptoms were found at day 6 in the intervention group than in the control group (all P<0.05). It was concluded that the neurotransmitter-precursor-supplement intervention is effective in alleviating the withdrawal and mood symptoms and it may become a supplementary method for patients' recovery from heroin addiction.
Administration, Oral ; Adult ; Dietary Supplements ; Drug Therapy, Combination ; methods ; Female ; Heroin Dependence ; diagnosis ; therapy ; Humans ; Male ; Neurotransmitter Agents ; administration & dosage ; Placebo Effect ; Single-Blind Method ; Substance Withdrawal Syndrome ; diagnosis ; drug therapy ; therapy ; Treatment Outcome